Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression and anxiety ‐ not reported · participants with chronic prostatitis/chronic pelvic pain syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression ‐ Not reported at long term · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health literacy – (1) Depression literacy · migrants
1 finding from 1 review
Disease‐related mental health: depression · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
1 finding from 1 review
Intervention not reported
Depression standardised depression scores · patients with sickle cell disease
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether dietary supplements (lycopene) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether physical barriers (tongue protector) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Psychological outcomes ‐ Distress and Depression · adults
1 finding from 1 review
Symptoms of depression at 3 months post‐treatment · health problem or population
1 finding from 1 review
Intervention not reported
Depression and anxiety at 3 to 8 months ‐ Anxiety · patients with treatment of inflammatory bowel disease
1 finding from 1 review
Depression symptoms ‐ short term (end of treatment) · health problem or population
1 finding from 1 review
Depression symptoms ‐ short term (end of treatment) · health problem or population
1 finding from 1 review
Beck Depression Inventory (BDI); higher score means more depression · people with CKD
It is very uncertain whether summary of findings: acupressure changes depression Beck Depression Inventory (BECK) (median compared with control (very low certainty).
1 finding from 1 review
Reduction in pain interference, depression,fatigu e · chronic pain in MS
1 finding from 1 review
Intervention not reported
Depressive symptoms Beck Depression Inventory Score · People living with HIV infection
1 finding from 1 review
Depression remission · health problem or population
1 finding from 1 review